<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7014709\results\search\drugs\results.xml">
  <result pre="in the half maximal inhibitory concentration for zidovudine, tenofovir, or" exact="lamivudine" post="between the K65R and K65R/S68G mutations, as demonstrated by"/>
  <result pre="were 301635, 301770, 301844, and 302335. The treatment regimens were" exact="tenofovir" post="(TDF), lamivudine (3TC), and efavirenz. Genotypic testing for drug"/>
  <result pre="301770, 301844, and 302335. The treatment regimens were tenofovir (TDF)," exact="lamivudine" post="(3TC), and efavirenz. Genotypic testing for drug resistance and"/>
  <result pre="4.BrennerBTurnerDOliveiraMMoisiDDetorioMCarobeneMMarlinkRGSchapiroJRogerMWainbergMAA V106M mutation in HIV-1 clade C viruses exposed to" exact="efavirenz" post="confers cross-resistance to non-nucleoside reverse transcriptase inhibitorsAIDS2003171F1F510.1097/00002030-200301030-0000112478089 5.Martinez-CajasJLWainbergMAOliveiraMAsahchopELDoualla-BellFLisovskyIMoisiDMendelsonEGrossmanZBrennerBGThe role"/>
  <result pre="resistance profile in vivo detected in most patients failing abacavir," exact="didanosine" post="and stavudineAntivir Ther20038217318212741630 21.Doualla-BellFAvalosABrennerBGaolatheTMineMGaseitsiweSOliveiraMMoisiDNdwapiNMoffatHet al.High prevalence of the K65R"/>
 </snippets>
</snippetsTree>
